United Kingdom Human Insulin Market Size, Share, and COVID-19 Impact Analysis, By Device (Pens, Syringes, and Others), By Indication (Type 1 Diabetes, Type 2 Diabetes, and Gestational Diabetes), and United Kingdom Human Insulin Market Insights, Industry Trend, Forecasts to 2035

United Kingdom Human Insulin Market Insights Forecasts to 2035

• The United Kingdom Human Insulin Market Size Was Estimated at USD 867.54 Million in 2024
• The Market Size is Expected to Grow at a CAGR of around 4.90% from 2025 to 2035
• The United Kingdom Human Insulin Market Size is Expected to Reach USD 1468.55 Million by 2035

According to a research report published by Spherical Insights and Consulting, The United Kingdom Human Insulin Market Size is anticipated to reach USD 1468.55 Million by 2035, growing at a CAGR of 4.90% from 2025 to 2035. The raising rates of diabetes, improving awareness regarding insulin treatments, improvements in insulin delivery systems, encouraging government programs, and an aging population that is more vulnerable to diabetes-related diseases.

Market Overview

The United Kingdom human insulin market refers to the industry focused on the creation, manufacturing, marketing, and distribution of insulin products for the treatment of diabetes.  It contains artificial human insulin and its derivatives, which are used to control blood sugar levels.  This market, which caters to individuals with Type 1 and Type 2 diabetes, is impacted by an assortment of variables, including government regulations, healthcare infrastructure, technological advancements, and the growing prevalence of diabetes in the UK. The minimizing the prevalence of diabetes, improving early diagnosis awareness, and expanding access to healthcare services. A favorable environment is produced by improvements in insulin delivery technologies, such as smart pens and pumps, encouraging government programs, and rising R&D expenditures. Furthermore, the development of biosimilar insulin products provides affordable substitutes, promoting market expansion and a wider patient base. The development of biosimilar insulin formulations, continuous glucose monitors with insulin delivery, and smart insulin pens.  These developments greatly improve diabetes management outcomes by increasing treatment precision, patient compliance, and affordability.

Report Coverage

This research report categorizes the market for the United Kingdom human insulin market based on various segments and regions and forecasts revenue growth and analyzes trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the United Kingdom human insulin market. Recent market developments and competitive strategies such as expansion, product launch, and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the United Kingdom human insulin market.

Driving Factors

The increasing rates of diabetes, especially Type 2, driven on by bad eating habits, aging populations, and sedentary lifestyles. Growing awareness of diabetes treatment and the significance of timely insulin administration also contributes to market expansion. Demand is also influenced by government programs to increase healthcare access and reimbursements, in addition to developments in insulin delivery devices including smart pens and pumps. Additionally, patients are more inclined to use biosimilar insulin products when they are less expensive. The market for insulin is growing as a consequence of strategic partnerships and ongoing innovation by pharmaceutical companies.

Restraining Factors

The limited access to innovative insulin treatments in rural locations, high production prices, and strict regulatory approvals. Adoption is also hampered by patient worries about injection pain and weight gain linked to insulin, and competition from biosimilars may affect existing brands' pricing and profitability.

Market Segmentation

The United Kingdom human insulin market share is classified into device and indication.

• The pens segment accounted for the largest share in 2024 and is expected to grow at a significant CAGR during the forecast period.

The United Kingdom human insulin market is segmented by device into pens, syringes, and others. Among these, the pens segment accounted for the largest share in 2024 and is expected to grow at a significant CAGR during the forecast period. The segment growth is driven by their portability, accuracy, ease of use, and improved patient adherence, especially among younger users and Type 1 diabetics searching for a discreet, pleasant, and dependable way to administer insulin throughout the day.

• The type 2 diabetes segment accounted for the largest revenue in 2024 and is expected to grow at a significant CAGR during the forecast period.

The United Kingdom human insulin market is segmented by indication into type 1 diabetes, type 2 diabetes, and gestational diabetes. Among these, the type 2 diabetes segment accounted for the largest revenue in 2024 and is expected to grow at a significant CAGR during the forecast period. This is because increasing insulin dependence in the course of the disease, rising prevalence of Type 2 diabetes as a consequence of age, obesity, and sedentary lifestyles, as well as increased knowledge of prenatal diabetes and ongoing need from patients with Type 1 diabetes who have had the condition their entire lives.

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the United Kingdom human insulin market along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

List of Key Companies

• Novo Nordisk A/S
• MannKind Corporation
• Pfizer
• Wockhardt
• Biocon
• Lupin
• Tonghua Dongbao Pharmaceutical Co
• Eli Lilly and Company
• AstraZeneca
• Others

Recent Developments:

• In September 2024, Novo Nordisk announced plans to gradually discontinue the production of human insulin pens globally, transitioning to vial-only formats. This strategic move aligns with the company's focus on expanding its portfolio of obesity and diabetes treatments, such as Wegovy and Ozempic.

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting and Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Market Segment

This study forecasts revenue at UK, regional, and country levels from 2020 to 2035. Spherical Insights has segmented the United Kingdom human insulin market based on the below-mentioned segments:

United Kingdom Human Insulin Market, By Device

• Pens
• Syringes
• Others

United Kingdom Human Insulin Market, By Indication

• Type 1 Diabetes
• Type 2 Diabetes
• Gestational Diabetes